Resumen
Background: Contemporary data regarding the temporal changes in prevalence and outcomes of hospitalizations with Prinzmetal angina are limited. Methods: We queried the National Inpatient Sample Database for the years 2002-2015 to identify hospitalizations with Prinzmetal angina. We described the temporal trends and outcomes in patients with Prinzmetal angina. Results: A total of 97,280 hospitalizations with Prinzmetal angina were identified. There was a significant increase in the number of hospitalizations with Prinzmetal angina (3678 in 2002 vs 8633 in 2015, Ptrend <.001) as well as the proportion of hospitalizations with Prinzmetal angina among those with chest pain (Ptrend <.001). There was an increase in the rates of in-hospital mortality (0.24% in 2002 vs 0.85% in 2015, Ptrend =.02), which corresponded to a progressive increase in the burden of comorbidities among patients with Prinzmetal angina. Age > 65 years, history of heart failure, chronic kidney disease, chronic liver disease, and acute myocardial infarction upon presentation were independent predictors of in-hospital mortality. Compared with patients with acute myocardial infarction without Prinzmetal angina, those with Prinzmetal angina presenting with acute myocardial infarction had a lower incidence of in-hospital mortality (odds ratio 0.24, 95% confidence interval 0.14-0.41). Conclusions: In this large national analysis, there has been an increase in the prevalence of hospitalizations with Prinzmetal angina. Older age, heart failure, chronic kidney disease, chronic liver disease, and acute myocardial infarction were predictors of higher mortality among patients with Prinzmetal angina. Patients with Prinzmetal angina who developed acute myocardial infarction had more favorable outcomes compared with myocardial infarction without Prinzmetal angina.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 1053-1061.e1 |
| Publicación | American Journal of Medicine |
| Volumen | 132 |
| N.º | 9 |
| DOI | |
| Estado | Published - sept 2019 |
Nota bibliográfica
Publisher Copyright:© 2019
Financiación
Funding: None. Conflict of Interest: AE, IYE, SYN, AHM, GOO, MAO, AM, MS, and HJ report no conflicts. DLB discloses the following relationships: Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, PLx Pharma, Takeda. JDA discloses the following relationships: research funding without direct compensation from Sinomed, Abbott Vascular, Bristol Myers Squibb, Astra Zeneca, Biosensors Research USA.
| Financiadores |
|---|
| Baim Institute for Clinical Research |
| Biosensors Research USA |
| Boston VA Research Institute, Society of Cardiovascular Patient Care |
| Harvard Clinical Research Institute |
| Population Health Research Institute |
| Sanofi Aventis, Synaptic, The Medicines Company |
| Slack Publications |
| Society of Cardiovascular Patient Care |
| VA CART |
| Mayo Clinic Rochester |
| Boehringer-Ingelheim |
| Abbott Laboratories |
| AMGen |
| Bristol-Myers Squibb |
| AstraZeneca |
| Merck |
| Roche Canada |
| American College of Cardiology Foundation |
| St. Jude Medical Center |
| Duke Clinical Research Institute |
| Icahn School of Medicine at Mount Sinai |
| Cleveland Clinic Foundation General Clinical Research Center of the Cleveland Clinic/Case Western Reserve University |
| Boston Scientific Neuromodulation Corporation |
| Abbott Vascular |
| Amarin Corporation |
| Bayer Fund |
| Belvoir Media Group |
| Daiichi Sankyo Company, Limited |
| Novo Nordisk Data Science |
| Biotronik Incorporated |
ASJC Scopus subject areas
- General Medicine
Huella
Profundice en los temas de investigación de 'Temporal Trends and Outcomes of Hospitalizations With Prinzmetal Angina: Perspectives From a National Database'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver